Top

Published in:

01-12-2011 | Opinion Paper

Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?

Authors: Elisabeth Ersvær, Guro Kristin Melve, Øystein Bruserud

Published in: Cancer Immunology, Immunotherapy | Issue 12/2011

Abstract

Th17 cells seem to promote proinflammatory effects, and their development seems to depend on intracellular signaling initiated by IL1β, supported by IL6 and IL23 and mediated by STAT3 and RORC2. Even though primary human AML cells may affect Th17 development through their constitutive cytokine release, the levels of circulating Th17 cells in older patients with untreated AML do not differ from healthy controls and show only minor variations during and following conventional intensive chemotherapy. IL17-A is the signature cytokine of Th17 cells, but in vitro studies have failed to demonstrate a direct antileukemic effect of IL17 on primary human AML cells for most patient samples. However, several observations suggest that Th17 cells mediate antileukemic effects through other mechanisms and are important in allogeneic stem cell transplantation. Firstly, genetic variants in IL23/Th17 pathway have a prognostic impact with regard to both development of GVHD and posttransplant infections. Secondly, circulating IL17-secreting cells are detected during early posttransplant pancytopenia, and their ability to release IL17 is associated with later GVHD. Thirdly, a high number of Th17 cells in allogeneic stem cell grafts are associated with later acute GVHD, levels of circulating Th17 cells are increased at the onset of acute GVHD, and these levels normalize during treatment. In the present article, we review previous studies of Th17 cells in AML and in the development of GVHD, possible therapeutic strategies and available therapeutic tools for targeting of Th17 cells.

Stutman O (1986) Postthymic T-cell development. Immunol Rev 91:159–194PubMedCrossRef

Tawara I, Shlomchik WD, Jones A, Zou W, Nieves E, Liu C, Toubai T, Duran-Struuck R, Sun Y, Clouthier SG, Evers R, Lowler KP, Levy RB, Reddy P (2010) A crucial role for host APCs in the induction of donor CD4⁺ CD25⁺ regulatory T cell-mediated suppression of experimental graft-versus-host disease. J Immunol 185(7):3866–3872. doi:10.4049/jimmunol.1001625 PubMedCrossRef

Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL (2005) A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 11(11):1244–1249. doi:10.1038/nm1309 PubMedCrossRef

Paczesny S, Hanauer D, Sun Y, Reddy P (2010) New perspectives on the biology of acute GVHD. Bone Marrow Transplant 45(1):1–11. doi:10.1038/bmt.2009.328 PubMedCrossRef

Li JM, Giver CR, Lu Y, Hossain MS, Akhtari M, Waller EK (2009) Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy 1(4):599–621PubMed

Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133–1141. doi:10.1038/ni1261 PubMedCrossRef

Annunziato F, Romagnani S (2010) The transient nature of the Th17 phenotype. Eur J Immunol 40(12):3312–3316. doi:10.1002/eji.201041145 PubMedCrossRef

Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L, Desai B, Faubion WA, de Waal Malefyt R, Pierce RH, McClanahan T, Kastelein RA (2009) Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206(3):525–534. doi:10.1084/jem.20081712 PubMedCrossRef

Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome SQ, Querci V, Fambrini M, Liotta F, Levings MK, Maggi E, Cosmi L, Romagnani S, Annunziato F (2010) CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 40(8):2174–2181. doi:10.1002/eji.200940257 PubMedCrossRef

10.

Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Abbate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F (2008) Human interleukin 17-producing cells originate from a CD161⁺ CD4⁺ T cell precursor. J Exp Med 205(8):1903–1916. doi:10.1084/jem.20080397 PubMedCrossRef

11.

Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA, Sheppard D (2010) Expression of alphavbeta8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice. J Clin Invest 120(12):4436–4444. doi:10.1172/JCI43786 PubMedCrossRef

12.

Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830–1835. doi:10.1002/eji.201040391 PubMedCrossRef

13.

Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448(7152):484–487. doi:10.1038/nature05970 PubMedCrossRef

14.

Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454(7202):350–352. doi:10.1038/nature07021 PubMedCrossRef

15.

Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O’Shea JJ (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 467(7318):967–971. doi:10.1038/nature09447 PubMedCrossRef

16.

Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8(9):942–949. doi:10.1038/ni1496 PubMedCrossRef

17.

Santarlasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, Liotta F, Cosmi L, Maggi E, Romagnani S, Annunziato F (2009) TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol 39(1):207–215. doi:10.1002/eji.200838748 PubMedCrossRef

18.

Valmori D, Raffin C, Raimbaud I, Ayyoub M (2010) Human RORgammat + TH17 cells preferentially differentiate from naive FOXP3 + Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA 107(45):19402–19407. doi:10.1073/pnas.1008247107 PubMedCrossRef

19.

Silva IA, Olkiewicz K, Askew D, Fisher JM, Chaudhary MN, Vannella KM, Deurloo DT, Choi SW, Pierce EM, Clouthier SG, Liu C, Cooke KR (2010) Secondary lymphoid organs contribute to, but are not required for the induction of graft-versus-host responses following allogeneic bone marrow transplantation: a shifting paradigm for T cell allo-activation. Biol Blood Marrow Transplant 16(5):598–611. doi:10.1016/j.bbmt.2009.12.007 PubMedCrossRef

20.

Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O’Shea JJ (2010) Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21(6):425–434. doi:10.1016/j.cytogfr.2010.10.006 PubMedCrossRef

21.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6):1121–1133. doi:10.1016/j.cell.2006.07.035 PubMedCrossRef

22.

Masters SL, Mielke LA, Cornish AL, Sutton CE, O’Donnell J, Cengia LH, Roberts AW, Wicks IP, Mills KH, Croker BA (2010) Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 11(8):640–646. doi:10.1038/embor.2010.93 PubMedCrossRef

23.

Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T, Radbruch A, Chang HD (2010) IFN-gamma and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol 40(11):3017–3027. doi:10.1002/eji.201040539 PubMedCrossRef

24.

Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S (2009) IFN-beta inhibits human Th17 cell differentiation. J Immunol 183(8):5418–5427. doi:10.4049/jimmunol.0803227 PubMedCrossRef

25.

Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P, Ferrari-Lacraz S, Dayer JM (2008) Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 112(9):3696–3703. doi:10.1182/blood-2008-05-155408 PubMedCrossRef

26.

Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, Kastelein RA, Cua DJ, de Waal Malefyt R (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206(3):535–548. doi:10.1084/jem.20082293 PubMedCrossRef

27.

Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861. doi:10.1084/jem.20070663 PubMedCrossRef

28.

Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, Basham B, Smith K, Chen T, Morel F, Lecron JC, Kastelein RA, Cua DJ, McClanahan TK, Bowman EP, de Waal Malefyt R (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8(9):950–957. doi:10.1038/ni1497 PubMedCrossRef

29.

Glenjen N, Hovland R, Wergeland L, Wendelbo O, Ernst P, Bruserud O (2003) The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status. Eur J Haematol 71(3):163–173PubMedCrossRef

30.

Kurschus FC, Croxford AL, Heinen AP, Wortge S, Ielo D, Waisman A (2010) Genetic proof for the transient nature of the Th17 phenotype. Eur J Immunol 40(12):3336–3346. doi:10.1002/eji.201040755 PubMedCrossRef

31.

Bruserud O (2010) The chemokine system in experimental and clinical hematology. Preface Curr Top Microbiol Immunol 341:v–vi

32.

Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, Turvey M, Brazzatti J, Gregor C, Nguyen P, Kara E, McColl SR (2010) An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation? CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays 32(12):1067–1076. doi:10.1002/bies.201000063 PubMedCrossRef

33.

Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM (2008) Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol 180(1):214–221PubMed

34.

Lim HW, Lee J, Hillsamer P, Kim CH (2008) Human Th17 cells share major trafficking receptors with both polarized effector T cells and FOXP3+ regulatory T cells. J Immunol 180(1):122–129PubMed

35.

Bruserud O, Ryningen A, Olsnes AM, Stordrange L, Oyan AM, Kalland KH, Gjertsen BT (2007) Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 92(3):332–341PubMedCrossRef

36.

Varona R, Cadenas V, Gomez L, Martinez AC, Marquez G (2005) CCR6 regulates CD4⁺ T-cell-mediated acute graft-versus-host disease responses. Blood 106(1):18–26. doi:10.1182/blood-2004-08-2996 PubMedCrossRef

37.

Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K (2005) CCR6 expression defines regulatory effector/memory-like cells within the CD25(+) CD4⁺ T-cell subset. Blood 105(7):2877–2886. doi:10.1182/blood-2004-07-2505 PubMedCrossRef

38.

Bruserud O (1999) Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia 13(8):1175–1187PubMedCrossRef

39.

Liu FL, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK, Chang DM (2007) Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology (Oxford) 46(8):1266–1273. doi:10.1093/rheumatology/kem055 CrossRef

40.

Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, Park SH, Lee SH, Kim HY (2007) Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford) 46(1):57–64. doi:10.1093/rheumatology/kel159 CrossRef

41.

Ersvaer E, Olsnes AM, Bruserud O (2007) The immunological dilemma: cellular innate and adaptive immune response versus human acute myeloid leukemia. Open Hematol Rev 1:1–14

42.

Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, Tefferi A, Elliot MA, Kaufmann SH, Mesa RA, Litzow MR (2006) Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20(1):29–34PubMedCrossRef

43.

Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, Markovic SN (2002) Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 16(7):1311–1318PubMedCrossRef

44.

Parkman R, Cohen G, Carter SL, Weinberg KI, Masinsin B, Guinan E, Kurtzberg J, Wagner JE, Kernan NA (2006) Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 12(9):919–927. doi:10.1016/j.bbmt.2006.05.008 PubMedCrossRef

45.

Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB (2006) Rapid helper T-cell recovery above 200 × 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 37(12):1119–1128. doi:10.1038/sj.bmt.1705381 PubMedCrossRef

46.

Williams KM, Hakim FT, Gress RE (2007) T cell immune reconstitution following lymphodepletion. Semin Immunol 19(5):318–330. doi:10.1016/j.smim.2007.10.004 PubMedCrossRef

47.

Auletta JJ, Lazarus HM (2005) Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 35(9):835–857. doi:10.1038/sj.bmt.1704966 PubMedCrossRef

48.

Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, Ghiringhelli F, Apetoh L, Chaput N, Flament C, Ullrich E, de Botton S, Zitvogel L, Kroemer G (2007) Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 220:22–34. doi:10.1111/j.1600-065X.2007.00567.x PubMedCrossRef

49.

Fredly H, Ersvaer E, Gjertsen BT, Bruserud O (2011) Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 25(6):1549–1556. doi:10.3892/or.2011.1229 PubMed

50.

Liseth K, Ersvaer E, Hervig T, Bruserud O (2010) Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010:692097. doi:10.1155/2010/692097 PubMedCrossRef

51.

Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 15(10):3325–3332. doi:10.1158/1078-0432.CCR-08-3010 PubMedCrossRef

52.

Wang X, Zheng J, Liu J, Yao J, He Y, Li X, Yu J, Yang J, Liu Z, Huang S (2005) Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 75(6):468–476. doi:10.1111/j.1600-0609.2005.00537.x PubMedCrossRef

53.

Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O (2010) Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 11:38. doi:10.1186/1471-2172-11-38 PubMedCrossRef

54.

Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, Briel J, Luznik L, Smith BD, Levitsky H, Karp JE (2011) Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 117(2):608–617. doi:10.1182/blood-2010-04-277939 PubMedCrossRef

55.

Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158(2):199–204. doi:10.1111/j.1365-2249.2009.04011.x PubMedCrossRef

56.

Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118(2):385–400PubMedCrossRef

57.

Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29(5):487–494. doi:10.1200/JCO.2010.30.1820 PubMedCrossRef

58.

Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HE, Kersey JH et al (1987) Risk factors for acute graft-versus-host disease. Br J Haematol 67(4):397–406PubMedCrossRef

59.

Chaidos A, Kanfer E, Apperley JF (2007) Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol 20(2):125–154. doi:10.1016/j.beha.2006.10.003 PubMedCrossRef

60.

Lowenberg B, van Putten WL, Ferrant A, Ossenkoppele G, Vellenga E, Verdonck LF, Gratwohl A, Boogaerts MA (1997) Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Stem Cells 15(Suppl 1):177–180. doi:10.1002/stem.5530150823 discussion 181PubMedCrossRef

61.

Anderlini P, Korbling M (1997) The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 15(1):9–17. doi:10.1002/stem.150009 PubMedCrossRef

62.

Korbling M, Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98(10):2900–2908PubMedCrossRef

63.

Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95(7):2269–2274PubMed

64.

Hill GR, Olver SD, Kuns RD, Varelias A, Raffelt NC, Don AL, Markey KA, Wilson YA, Smyth MJ, Iwakura Y, Tocker J, Clouston AD, Macdonald KP (2010) Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood 116(5):819–828. doi:10.1182/blood-2009-11-256495 PubMedCrossRef

65.

Sun LX, Ren HY, Shi YJ, Wang LH, Qiu ZX (2009) Recombinant human granulocyte colony-stimulating factor significantly decreases the expression of CXCR3 and CCR6 on T cells and preferentially induces T helper cells to a T helper 17 phenotype in peripheral blood harvests. Biol Blood Marrow Transplant 15(7):835–843. doi:10.1016/j.bbmt.2009.03.016 PubMedCrossRef

66.

Toh HC, Sun L, Soe Y, Wu Y, Phoon YP, Chia WK, Wu J, Wong KY, Tan P (2009) G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo. Clin Immunol 132(1):83–92. doi:10.1016/j.clim.2009.03.509 PubMedCrossRef

67.

Zhao XY, Xu LL, Lu SY, Huang XJ (2011) IL-17-producing T cells contribute to acute graft-versus-host disease in patients undergoing unmanipulated blood and marrow transplantation. Eur J Immunol 41(2):514–526. doi:10.1002/eji.201040793 PubMedCrossRef

68.

Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce R, McClanahan TK, Sadekova S, de Waal Malefyt R (2010) Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol 185(1):679–687. doi:10.4049/jimmunol.1000366 PubMedCrossRef

69.

Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8(6):639–646. doi:10.1038/ni1467 PubMedCrossRef

70.

Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ (2010) T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 16(2):170–178. doi:10.1016/j.bbmt.2009.09.023 PubMedCrossRef

71.

Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS (2009) In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113(6):1365–1374. doi:10.1182/blood-2008-06-162420 PubMedCrossRef

72.

Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR (2007) Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110(10):3804–3813. doi:10.1182/blood-2007-05-091074 PubMedCrossRef

73.

Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, LeBon T, Kandeel F, Forman S, Zeng D (2008) Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112(5):2101–2110. doi:10.1182/blood-2007-12-126987 PubMedCrossRef

74.

Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR (1998) Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 102(9):1742–1748. doi:10.1172/JCI3906 PubMedCrossRef

75.

Yang YG, Dey BR, Sergio JJ, Pearson DA, Sykes M (1998) Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. J Clin Invest 102(12):2126–2135. doi:10.1172/JCI4992 PubMedCrossRef

76.

Carvalho A, Cunha C, Di Ianni M, Pitzurra L, Aloisi T, Falzetti F, Carotti A, Bistoni F, Aversa F, Romani L (2010) Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplant 45(11):1645–1652. doi:10.1038/bmt.2010.28 PubMedCrossRef

77.

Liseth K, Sjo M, Paulsen K, Bruserud O, Ersvaer E (2010) Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. Eur Cytokine Netw 21(1):40–49. doi:10.1684/ecn.2009.0181 PubMed

78.

Catusse J, Parry CM, Dewin DR, Gompels UA (2007) Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization. Blood 109(9):3633–3639. doi:10.1182/blood-2006-08-042622 PubMedCrossRef

79.

Engelhardt BG, Crowe JE, Jr. (2010) Homing in on acute graft versus host disease: tissue-specific T regulatory and Th17 cells. Curr Top Microbiol Immunol 341:121-146. doi:10.1007/82_2010_24

80.

Kittan NA, Hildebrandt GC (2010) The chemokine system: a possible therapeutic target in acute graft versus host disease. Curr Top Microbiol Immunol 341:97–120. doi:10.1007/82_2010_23 PubMedCrossRef

81.

Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 14(2):246–255. doi:10.1016/j.bbmt.2007.11.012 PubMedCrossRef

82.

Roddie C, Peggs KS (2011) Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11(4):473–487. doi:10.1517/14712598.2011.554811 PubMedCrossRef

83.

Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108–3114. doi:10.1182/blood-2002-02-0506 PubMedCrossRef

84.

Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P, Yanlan H (2011) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol J 8:17. doi:10.1186/1743-422X-8-17 PubMedCrossRef

85.

Wilhelm K, Ganesan J, Muller T, Durr C, Grimm M, Beilhack A, Krempl CD, Sorichter S, Gerlach UV, Juttner E, Zerweck A, Gartner F, Pellegatti P, Di Virgilio F, Ferrari D, Kambham N, Fisch P, Finke J, Idzko M, Zeiser R (2010) Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16(12):1434–1438. doi:10.1038/nm.2242 PubMedCrossRef

86.

Nakase H, Matsuura M, Uza N, Chiba T (2011) Tacrolimus suppresses IL-12/IL23 p40 in Crohn’s disease and heals fistulae refractory to anti-TNF-alpha therapy. Aliment Pharmacol Ther 33 (8):979–980; author reply 980–981. doi:10.1111/j.1365-2036.2011.04587.x

87.

Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH (1998) Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130. Leuk Lymphoma 31(5–6):551–558. doi:10.3109/10428199809057614 PubMed

88.

Marti L, Golmia R, Golmia AP, Paes AT, Guilhen DD, Moreira-Filho CA, Scheinberg M (2009) Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. Ann NY Acad Sci 1173:334–342. doi:10.1111/j.1749-6632.2009.04740.x PubMedCrossRef

89.

Quartier P, Allantaz F, Cimaz R, Pillet P, Messiaen C, Bardin C, Bossuyt X, Boutten A, Bienvenu J, Duquesne A, Richer O, Chaussabel D, Mogenet A, Banchereau J, Treluyer JM, Landais P, Pascual V (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70(5):747–754. doi:10.1136/ard.2010.134254 PubMedCrossRef

90.

Pease JE, Horuk R (2009) Chemokine receptor antagonists: part 2. Expert Opin Ther Pat 19(2):199–221. doi:10.1517/13543770802641353 PubMedCrossRef

91.

Pease JE, Horuk R (2009) Chemokine receptor antagonists: part 1. Expert Opin Ther Pat 19(1):39–58. doi:10.1517/13543770802641346 PubMedCrossRef

92.

Proudfoot AE, Power CA, Schwarz MK (2010) Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 19(3):345–355. doi:10.1517/13543780903535867 PubMedCrossRef

93.

Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H, Young J, Todorov I, Umetsu DT, Chen L, Iwakura Y, Kandeel F, Forman S, Zeng D (2009) Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114(14):3101–3112. doi:10.1182/blood-2009-05-219402 PubMedCrossRef

Title: Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?
Authors: Elisabeth Ersvær
Guro Kristin Melve
Øystein Bruserud
Publication date: 01-12-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 12/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1118-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2011

Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses

A critical role for regulatory T cells in driving cytokine profiles of Th17 cells and their modulation of glioma microenvironment

In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells

Prognostic impact of B-cell density in cutaneous melanoma

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients

Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer